Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PET-RIMCEB: Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patients A phase III study A randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas + A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas.

Next Previous
X
Search
Trial Profile

PET-RIMCEB: Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patients A phase III study A randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas + A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Melphalan; Prednisolone; Vincristine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PET-RIMCEB

    • Most Recent Events

    • 20 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top